Jan 11, 2023 / 05:45PM GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the Hikma presentation. You're going to hear from Bassam Kanaan, Corporate Development and M&A. And then we're going to do a breakout setup here, where we're also going to be joined by Susan Ringdal, Global Affairs and Strategic Planning. Thanks very much for coming today and looking forward to the presentation.
Bassam Wael Rushdi Kanaan - Hikma Pharmaceuticals PLC - EVP of Corporate Development and M&A
Good morning, everyone. I'm very happy to be here. The usual disclaimer to start with. Actually, I've been in Hikma for 20 years. And in this period of time, we went from a small company founded in Jordan, with sales of less than $100 million to a global company listed on the London Stock Exchange with sales of $2.5 billion. It has been an incredible journey for me and a privilege to be part of this growth. Today, I truly believe that our business is
Hikma Pharmaceuticals PLC at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers